CY1105809T1 - Αναστολεις της αλληλεπιδρασης πυρηνικης πρωτεϊνης /πυρηνικου υποδοχεα - Google Patents

Αναστολεις της αλληλεπιδρασης πυρηνικης πρωτεϊνης /πυρηνικου υποδοχεα

Info

Publication number
CY1105809T1
CY1105809T1 CY20061101715T CY061101715T CY1105809T1 CY 1105809 T1 CY1105809 T1 CY 1105809T1 CY 20061101715 T CY20061101715 T CY 20061101715T CY 061101715 T CY061101715 T CY 061101715T CY 1105809 T1 CY1105809 T1 CY 1105809T1
Authority
CY
Cyprus
Prior art keywords
nuclear
protein
nuclear protein
nuclear receptor
signature motif
Prior art date
Application number
CY20061101715T
Other languages
English (en)
Inventor
David Michael Heery
Malcolm George Parker
Original Assignee
Imperial Cancer Research Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Cancer Research Technology Limited filed Critical Imperial Cancer Research Technology Limited
Publication of CY1105809T1 publication Critical patent/CY1105809T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Μία μέθοδος για την αναγνώριση ενώσεων αναστολέα ικανών να μειώνουν την αλληλεπίδραση μεταξύ μίας πρώτης περιοχής η οποία είναι ένα μοτίφ υπογραφή σε μία πυρηνική πρωτεΐνη, και μίας δεύτερης περιοχής η οποία είναι ικανή ν' αλληλεπιδρά με την πυρηνική πρωτεΐνη μέσω σύνδεσης στο μοτίφ υπογραφή, όπου: η πυρηνική πρωτεΐνη είναι ένας παράγοντας γεφύρωσης που ευθύνεται για την αλληλεπίδραση μεταξύ ενός συνδεδεμένου πυρηνικού υποδοχέα κι ενός συμπλόκου έναρξης μεταγραφής που εμπλέκεται στη ρύθμιση της γονιδιακής έκφρασης· ο πυρηνικός υποδοχέας είναι ένας παράγοντας μεταγραφής, το μοτίφ υπογραφή είναι μία μικρή αλληλουχία αμινοξικών υπολειμμάτων που είναι το δομικό στοιχείο κλειδί μίας πυρηνικής πρωτεΐνης η οποία δεσμεύεται μ' ένα συνδεδεμένο πυρηνικό υποδοχέα ως τμήμα της διαδικασίας της ενεργοποίησης ή καταστολής των γονιδίων στόχων.
CY20061101715T 1997-04-30 2006-11-29 Αναστολεις της αλληλεπιδρασης πυρηνικης πρωτεϊνης /πυρηνικου υποδοχεα CY1105809T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9708676.3A GB9708676D0 (en) 1997-04-30 1997-04-30 Chemical compounds
PCT/GB1998/001238 WO1998049561A1 (en) 1997-04-30 1998-04-28 Inhibitors of nuclear protein/nuclear receptor interaction

Publications (1)

Publication Number Publication Date
CY1105809T1 true CY1105809T1 (el) 2011-02-02

Family

ID=10811533

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101715T CY1105809T1 (el) 1997-04-30 2006-11-29 Αναστολεις της αλληλεπιδρασης πυρηνικης πρωτεϊνης /πυρηνικου υποδοχεα

Country Status (11)

Country Link
EP (1) EP0980526B1 (el)
JP (2) JP2002512690A (el)
AT (1) ATE338276T1 (el)
AU (1) AU7220798A (el)
CY (1) CY1105809T1 (el)
DE (1) DE69835741T2 (el)
DK (1) DK0980526T3 (el)
ES (1) ES2271993T3 (el)
GB (1) GB9708676D0 (el)
PT (1) PT980526E (el)
WO (1) WO1998049561A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101681B1 (en) * 1997-11-21 2006-09-05 Amgen, Inc. Nuclear hormone receptor drug screens
US6303576B1 (en) * 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression
US20040137441A1 (en) * 2003-01-15 2004-07-15 Isis Pharmaceuticals Inc. Modulation of thyroid hormone receptor interactor 3 expression
GB0215496D0 (en) * 2002-07-04 2002-08-14 Imp College Innovations Ltd Screening for anti-ovulatory compounds
JP6700186B2 (ja) * 2014-01-22 2020-05-27 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 療法の適合性を評価するための改善された患者の層別化

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2257110A1 (en) * 1996-05-31 1997-12-04 American Cyanamid Company Screen for ultraspiracle inhibitors
EP0939810B1 (en) * 1996-07-12 2007-02-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Transcriptional intermediary factor-2 tif2
US5877282A (en) * 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof

Also Published As

Publication number Publication date
PT980526E (pt) 2006-12-29
EP0980526A1 (en) 2000-02-23
GB9708676D0 (en) 1997-06-18
EP0980526B1 (en) 2006-08-30
ATE338276T1 (de) 2006-09-15
JP2007304102A (ja) 2007-11-22
AU7220798A (en) 1998-11-24
DE69835741D1 (de) 2006-10-12
ES2271993T3 (es) 2007-04-16
DE69835741T2 (de) 2007-09-13
WO1998049561A1 (en) 1998-11-05
JP4206420B2 (ja) 2009-01-14
DK0980526T3 (da) 2006-12-04
JP2002512690A (ja) 2002-04-23

Similar Documents

Publication Publication Date Title
Bourgeois et al. Spt5 cooperates with human immunodeficiency virus type 1 Tat by preventing premature RNA release at terminator sequences
Zhao et al. SAR‐dependent mobilization of histone H1 by HMG‐I/Y in vitro: HMG‐I/Y is enriched in H1‐depleted chromatin.
Henderson et al. Interactions between HIV Rev and nuclear import and export factors: the Rev nuclear localisation signal mediates specific binding to human importin-β
Görlach et al. The determinants of RNA-binding specificity of the heterogeneous nuclear ribonucleoprotein C proteins.
Janknecht et al. Elk-1 protein domains required for direct and SRF-assisted DNA-binding
Howe RNA polymerase II conducts a symphony of pre-mRNA processing activities
CY1105809T1 (el) Αναστολεις της αλληλεπιδρασης πυρηνικης πρωτεϊνης /πυρηνικου υποδοχεα
Wemmer Ligands recognizing the minor groove of DNA: development and applications
Mossi et al. DNA polymerase switching: II. Replication factor C abrogates primer synthesis by DNA polymerase α at a critical length
He et al. New insights into the control of HIV-1 transcription: when Tat meets the 7SK snRNP and super elongation complex (SEC)
Bellorini et al. Distamycin A and tallimustine inhibit TBP binding and basal in vitro transcription
NO962991D0 (no) Zink-finger-proteinderivater og fremgangsmåter
Soros et al. Inhibition of human immunodeficiency virus type 1 Rev function by a dominant-negative mutant of Sam68 through sequestration of unspliced RNA at perinuclear bundles
TenHarmsel et al. Cooperative binding at a distance by even-skipped protein correlates with repression and suggests a mechanism of silencing
Shin et al. Gene silencing by H‐NS from distal DNA site
Greco-Stewart et al. Binding of the polypyrimidine tract-binding protein-associated splicing factor (PSF) to the hepatitis delta virus RNA
Belshan et al. Binding of equine infectious anemia virus rev to an exon splicing enhancer mediates alternative splicing and nuclear export of viral mRNAs
BRPI0506148A (pt) preparação farmacêutica para o tratamento de choque
Zhou et al. A bimolecular mechanism of HIV-1 Tat protein interaction with RNA polymerase II transcription elongation complexes
Lobov et al. Specificity of SAF‐A and lamin B binding in vitro correlates with the satellite DNA bending state
SWAMYNATHAN et al. Chicken Y-box proteins chk-YB-1b and chk-YB-2 repress translation by sequence-specific interaction with single-stranded RNA
Sharma et al. Binding of the bacteriophage T4 transcriptional activator, MotA, to T4 middle promoter DNA: evidence for both major and minor groove contacts
Ghimire Gautam et al. Strong Inhibition of Beta‐Amyloid Peptide Aggregation Realized by Two‐Steps Evolved Peptides
Berger et al. Exploring the polyamine regulatory site of the NMDA receptor: a parallel synthesis approach
Marmillot et al. Enhancement of transcription factor, USF, binding to the adenovirus major late promoter: effect of dithiothreitol and high mobility group protein-1